Genmab — December 2019
-
What advice can you offer to community hematologists and oncologists treating patients with transplant-ineligible NDMM?
Dr. Mateos: Always try to use the best combination first because the best combinations will benefit almost 100% of newly diagnosed myeloma patients. The maximum benefit is obtained from the first line of therapy, and some transplant-ineligible patients with NDMM will receive only one line of therapy. https://i3health.us/news/adding-daratumumab-to-vmp-for-transplant-ineligible
-
-
Glaxo’s myeloma Dreamm turns into a nightmare https://www.evaluate.com/vantage/articles/news/trial-results/glaxos-myeloma-dreamm-turns-nightmare
-
Maybe this link is better ? http://digitaledition.qwinc.com/publication/?i=641494&ver=html5&p=16
-
-
Kunne man håbe, at Novartis er den anonyme køber https://ml-eu.globenewswire.com/Resource/Download/3d403113-b3d8-47e1-b152-6ce5e26c3d60
-
Så de kan bruge den til at få Ofa MS hurtigere godkendt, og på markedet...
-
God morgen.

-
-
I see Genmab is also included in this Blackrock ETF, iShares Genomics Immunology and Healthcare ETF https://www.blackrock.com/us/individual/products/308878/
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind